TWI884224B - 縮合三環性化合物及其醫藥用途 - Google Patents
縮合三環性化合物及其醫藥用途 Download PDFInfo
- Publication number
- TWI884224B TWI884224B TW110107548A TW110107548A TWI884224B TW I884224 B TWI884224 B TW I884224B TW 110107548 A TW110107548 A TW 110107548A TW 110107548 A TW110107548 A TW 110107548A TW I884224 B TWI884224 B TW I884224B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- group
- substituted
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11002—[Pyruvate dehydrogenase (acetyl-transferring)] kinase (2.7.11.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-036931 | 2020-03-04 | ||
| JP2020036931 | 2020-03-04 | ||
| JP2021001452 | 2021-01-07 | ||
| JP2021-001452 | 2021-01-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202146410A TW202146410A (zh) | 2021-12-16 |
| TWI884224B true TWI884224B (zh) | 2025-05-21 |
Family
ID=77613417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110107548A TWI884224B (zh) | 2020-03-04 | 2021-03-03 | 縮合三環性化合物及其醫藥用途 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20230025880A1 (enExample) |
| EP (2) | EP4116301B1 (enExample) |
| JP (2) | JP7739012B2 (enExample) |
| KR (1) | KR20220149688A (enExample) |
| CN (1) | CN115151543B (enExample) |
| AU (1) | AU2021230880A1 (enExample) |
| BR (1) | BR112022014749A2 (enExample) |
| CA (1) | CA3166747A1 (enExample) |
| CL (1) | CL2022002355A1 (enExample) |
| CO (1) | CO2022012548A2 (enExample) |
| DK (1) | DK4116301T3 (enExample) |
| ES (1) | ES3052010T3 (enExample) |
| FI (1) | FI4116301T3 (enExample) |
| HR (1) | HRP20251364T1 (enExample) |
| IL (1) | IL295836B1 (enExample) |
| LT (1) | LT4116301T (enExample) |
| MX (1) | MX2022010950A (enExample) |
| PE (1) | PE20221908A1 (enExample) |
| PH (1) | PH12022552259A1 (enExample) |
| PT (1) | PT4116301T (enExample) |
| TW (1) | TWI884224B (enExample) |
| WO (1) | WO2021177330A1 (enExample) |
| ZA (1) | ZA202209620B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006916SA (en) * | 2018-02-01 | 2020-08-28 | Japan Tobacco Inc | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
| TWI884224B (zh) * | 2020-03-04 | 2025-05-21 | 日商日本煙草產業股份有限公司 | 縮合三環性化合物及其醫藥用途 |
| TW202319051A (zh) * | 2021-09-01 | 2023-05-16 | 日商日本煙草產業股份有限公司 | 含氮三環性化合物及其醫藥用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017020981A1 (en) * | 2015-07-31 | 2017-02-09 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| WO2019151274A1 (ja) * | 2018-02-01 | 2019-08-08 | 日本たばこ産業株式会社 | 含窒素複素環アミド化合物及びその医薬用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1615647T3 (da) * | 2003-04-11 | 2010-04-06 | High Point Pharmaceuticals Llc | Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| KR100808551B1 (ko) * | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| KR102226096B1 (ko) * | 2013-03-15 | 2021-03-09 | 니뽄 다바코 산교 가부시키가이샤 | 피라졸-아미드 화합물 및 그의 의약 용도 |
| WO2020054734A1 (ja) | 2018-09-11 | 2020-03-19 | 日本たばこ産業株式会社 | ピラゾール－アミド化合物を含有する慢性腎臓病の治療又は予防剤 |
| TWI884224B (zh) * | 2020-03-04 | 2025-05-21 | 日商日本煙草產業股份有限公司 | 縮合三環性化合物及其醫藥用途 |
-
2021
- 2021-03-03 TW TW110107548A patent/TWI884224B/zh active
- 2021-03-03 DK DK21764169.5T patent/DK4116301T3/da active
- 2021-03-03 LT LTEPPCT/JP2021/008055T patent/LT4116301T/lt unknown
- 2021-03-03 FI FIEP21764169.5T patent/FI4116301T3/fi active
- 2021-03-03 WO PCT/JP2021/008055 patent/WO2021177330A1/ja not_active Ceased
- 2021-03-03 MX MX2022010950A patent/MX2022010950A/es unknown
- 2021-03-03 ES ES21764169T patent/ES3052010T3/es active Active
- 2021-03-03 KR KR1020227032125A patent/KR20220149688A/ko active Pending
- 2021-03-03 CN CN202180018517.1A patent/CN115151543B/zh active Active
- 2021-03-03 CA CA3166747A patent/CA3166747A1/en active Pending
- 2021-03-03 US US17/602,103 patent/US20230025880A1/en active Pending
- 2021-03-03 PT PT217641695T patent/PT4116301T/pt unknown
- 2021-03-03 EP EP21764169.5A patent/EP4116301B1/en active Active
- 2021-03-03 IL IL295836A patent/IL295836B1/en unknown
- 2021-03-03 PE PE2022001891A patent/PE20221908A1/es unknown
- 2021-03-03 PH PH1/2022/552259A patent/PH12022552259A1/en unknown
- 2021-03-03 BR BR112022014749A patent/BR112022014749A2/pt unknown
- 2021-03-03 HR HRP20251364TT patent/HRP20251364T1/hr unknown
- 2021-03-03 JP JP2021033150A patent/JP7739012B2/ja active Active
- 2021-03-03 AU AU2021230880A patent/AU2021230880A1/en active Pending
- 2021-03-03 EP EP25206111.4A patent/EP4663189A2/en active Pending
-
2022
- 2022-08-29 ZA ZA2022/09620A patent/ZA202209620B/en unknown
- 2022-08-29 CL CL2022002355A patent/CL2022002355A1/es unknown
- 2022-09-01 CO CONC2022/0012548A patent/CO2022012548A2/es unknown
-
2025
- 2025-09-03 JP JP2025145992A patent/JP2025175000A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017020981A1 (en) * | 2015-07-31 | 2017-02-09 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| WO2019151274A1 (ja) * | 2018-02-01 | 2019-08-08 | 日本たばこ産業株式会社 | 含窒素複素環アミド化合物及びその医薬用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4663189A2 (en) | 2025-12-17 |
| IL295836A (en) | 2022-10-01 |
| JP2022007994A (ja) | 2022-01-13 |
| TW202146410A (zh) | 2021-12-16 |
| CN115151543B (zh) | 2024-12-17 |
| EP4116301A4 (en) | 2024-04-03 |
| WO2021177330A1 (ja) | 2021-09-10 |
| PE20221908A1 (es) | 2022-12-23 |
| JP7739012B2 (ja) | 2025-09-16 |
| CO2022012548A2 (es) | 2022-09-20 |
| CL2022002355A1 (es) | 2023-03-03 |
| ZA202209620B (en) | 2023-12-20 |
| CA3166747A1 (en) | 2021-09-10 |
| MX2022010950A (es) | 2022-10-07 |
| HRP20251364T1 (hr) | 2025-12-19 |
| PH12022552259A1 (en) | 2023-11-20 |
| BR112022014749A2 (pt) | 2022-10-11 |
| FI4116301T3 (fi) | 2025-12-19 |
| JP2025175000A (ja) | 2025-11-28 |
| CN115151543A (zh) | 2022-10-04 |
| EP4116301A1 (en) | 2023-01-11 |
| PT4116301T (pt) | 2025-11-12 |
| US20230025880A1 (en) | 2023-01-26 |
| IL295836B1 (en) | 2025-09-01 |
| KR20220149688A (ko) | 2022-11-08 |
| AU2021230880A1 (en) | 2022-09-29 |
| ES3052010T3 (en) | 2025-12-30 |
| LT4116301T (lt) | 2025-11-10 |
| DK4116301T3 (da) | 2025-10-20 |
| EP4116301B1 (en) | 2025-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI884224B (zh) | 縮合三環性化合物及其醫藥用途 | |
| CN103052637B (zh) | 醛糖还原酶抑制剂及其用途 | |
| EP3091003B1 (en) | 1,2-naphthoquinone derivative and method for preparing same | |
| KR102725118B1 (ko) | 질소 함유 복소환 아미드 화합물 및 그의 의약 용도 | |
| KR20190035870A (ko) | Fgfr 저해제로서 헤테로시클릭 화합물 | |
| WO2008129152A1 (fr) | Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations | |
| JP5820080B2 (ja) | 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤 | |
| KR20220113771A (ko) | 마크로사이클릭 구조를 갖는 불소-함유 헤테로사이클릭 유도체 및 이의 용도 | |
| WO2025130971A1 (zh) | 稠环化合物、包含其的药物组合物及其用途 | |
| CN119707953A (zh) | 噻二唑烷酮衍生物及其制备方法和应用 | |
| CN118184658A (zh) | Usp1抑制剂 | |
| JP2024521900A (ja) | メチオニンアデノシルトランスフェラーゼ２ａ阻害剤 | |
| RU2833338C1 (ru) | Конденсированное трициклическое соединение и его применение в медицине | |
| TW202319051A (zh) | 含氮三環性化合物及其醫藥用途 | |
| HK40077808B (en) | Fused tricyclic compound and medicinal use thereof | |
| HK40077808A (en) | Fused tricyclic compound and medicinal use thereof | |
| WO2019080724A1 (zh) | 核苷磷酸类化合物及其制备方法和用途 | |
| US20250361240A1 (en) | Pyranopyridine compound, process for preparing the same, pharmaceutical composition and use thereof | |
| JP4595103B2 (ja) | 新規４，５，６，７−テトラヒドロ−［１，２］ジチオロ［４，３−ｃ］ピリジン−３−チオン系化合物 | |
| CN117430606A (zh) | 磺酰胺类parp7抑制剂 | |
| HK40116576A (en) | Nitrogen-containing tricyclic compound and pharmaceutical use thereof | |
| CN104684559A (zh) | 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂 |